Australian Biotech Solagran Registers New Pharmaceutical in Russia

Sydney, July 18, 2007 (ACN Newswire) - Australian Biotech Solagran Limited (ASX: SLA) today announced that it had received formal documentation from the Russian Ministry of Heath advising that pharmaceutical registration of both its substance Bioeffective® R and the associated medicine Ropren has been finalised. Ropren is a safe and effective natural hepatoprotector which will be used to treat chronic liver disease, including hepatitis and cirrhosis.

MORE ON THIS TOPIC